{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:39:54Z","timestamp":1786977594981,"version":"build-2736575974"},"reference-count":9,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin &amp; Trans Imm"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate within\u2010patient symptom improvement in the dupilumab SINUS\u201024\/\u201052 studies in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT02912468\/NCT02898454).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients received dupilumab 300\u2009mg or placebo every 2\u2009weeks for 24 (SINUS\u201024) or 52\u2009weeks (SINUS\u201052) on background intranasal corticosteroids. Patients daily reported symptoms of nasal congestion (NC), loss of smell (LoS) and rhinorrhoea on a scale of 0\u20133 (0 \u2013 no symptoms, 1 \u2013 mild, 2 \u2013 moderate, 3 \u2013 severe symptoms). The proportions of patients with moderate\u2010to\u2010severe symptoms (score\u2009\u2265\u20092) at baseline who improved to no\u2010to\u2010mild symptoms (score\u2009\u2264\u20091) were determined at Weeks 2, 24 (pooled studies) and 52 (SINUS\u201052). Subgroups with prior sinonasal surgery and coexisting asthma were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline in the pooled intention\u2010to\u2010treat population (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0724), the proportions of patients with scores\u2009\u2265\u20092 for NC, LoS and rhinorrhoea were 87, 94 and 64%, respectively. Significantly, more patients achieved scores\u2009\u2264\u20091 (no\/mild symptoms) with dupilumab vs placebo for each symptom at each time point {Week 2 NC 12% vs 2% [odds ratio 8.9 (95% CI 3.0\u201326.3)], LoS 5% vs 1% [4.6 (1.3\u201316.8)], rhinorrhoea 9% vs 2% [4.8 (1.5\u201315.4)], all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05; Week 24 NC 54% vs 14% [8.7 (5.6\u201313.5)], LoS 43% vs 6% [14.4 (7.9\u201326.0)], rhinorrhoea 53% vs 16% [6.6 (4.1\u201310.9)], all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001}. Results were similar in subgroups with prior surgery and coexisting asthma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Significantly, more patients achieved improvement from moderate\u2010to\u2010severe symptoms to no\u2010to\u2010mild symptoms with dupilumab than placebo, regardless of prior surgery or coexisting asthma. Improvement was observed as early as Week 2 and continued through to Week 52.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cti2.1433","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T07:53:40Z","timestamp":1674806020000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dupilumab provides early and durable improvement of\u00a0symptoms in patients with chronic rhinosinusitis with\u00a0nasal polyps"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-8468","authenticated-orcid":false,"given":"Philippe","family":"Gevaert","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology Ghent University Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6563-6606","authenticated-orcid":false,"given":"Stella E","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2014Head &amp; Neck Surgery Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-8780","authenticated-orcid":false,"given":"Russell A","family":"Settipane","sequence":"additional","affiliation":[{"name":"Department of Medicine The Warren Alpert Medical School of Brown University Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9734-0241","authenticated-orcid":false,"given":"Martin","family":"Wagenmann","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology D\u00fcsseldorf University Hospital (UKD) D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Msihid","sequence":"additional","affiliation":[{"name":"Health Economics and Value Assessment, Sanofi Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Medical Affairs, Regeneron Pharmaceuticals Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Nash","sequence":"additional","affiliation":[{"name":"Medical Affairs, Regeneron Pharmaceuticals Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A","family":"Jacob\u2010Nara","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif H","family":"Khan","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhesh","family":"Kamat","sequence":"additional","affiliation":[{"name":"Medical Affairs, Regeneron Pharmaceuticals Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien\u2010Chia","family":"Chuang","sequence":"additional","affiliation":[{"name":"Health Economics and Value Assessment, Sanofi Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin17.255"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2012.02527.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S290424"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.401"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1298443"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_2_9_8_1","unstructured":"DUPIXENT\u00ae (dupilumab).Prescribing information Regeneron Pharmaceuticals[PDF on Internet; updated June 2021; cited November 24 2020]. Available from:https:\/\/www.regeneron.com\/sites\/default\/files\/Dupixent_FPI.pdf"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29888"}],"container-title":["Clinical &amp; Translational Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cti2.1433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cti2.1433","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cti2.1433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T16:28:36Z","timestamp":1692462516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cti2.1433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/cti2.1433"],"URL":"https:\/\/doi.org\/10.1002\/cti2.1433","archive":["Portico"],"relation":{},"ISSN":["2050-0068","2050-0068"],"issn-type":[{"value":"2050-0068","type":"print"},{"value":"2050-0068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1433"}}